Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 17, Issue 5, 1998, Pages 411-418

  Rivera, Seth ^a   Briggs, William ^a   Qian, Dajun ^a   Sattler, Fred R ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

Body composition; Body mass index; HIV RNA; Proinflammatory cytokines; Wasting; Weight loss patterns

Indexed keywords

VIRUS RNA;

ADULT; AGED; AIDS RELATED COMPLEX; ARTICLE; CACHEXIA; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RNA ANALYSIS; VIRUS DETECTION; VIRUS LOAD; WEIGHT REDUCTION;

EID: 0032522079     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199804150-00005     Document Type: Article

References (40)

1. Weiss PJ, Wallace MR, Olson PE, Rossetti R. Changes in the mix of AIDS defining conditions. N Engl J Med 1993;329:1056.
2. Morbidity and Mortality Weekly Report. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;4:1-13.
3. Chan ISF, Neaton LD, Saravolatz LR, Crane LR, Osterberger J. Frequencies of opportunistic diseases prior to death among HIV-infected persons. AIDS 1995;9:1145-52.
4. Macallan DC, Noble C, Baldwin C, Foskett M, McManus T, Griffin GE. Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr 1993; 58:417-24.
5. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:329-37.
6. Melchior J-C, Salmon D, Rigaud D, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 1991;53:437-41.
7. Hommes MJT, Romijn JA, Enden E, Sauerwein HP. Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr 1991; 54:311-5.
8. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992;55: 455-60.
9. Mulligan K, Tai VW, Schambelan M. Energy expenditure in human immunodeficiency virus infection. N Engl J Med 1997;336: 70-1.
10. Roubenoff R, Skolnik P, Knox T, et al. Determinants of metabolic rate and body composition in adults with HIV infection [abstract No. B. 1393]. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, 1996.
11. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double-blind, placebo-controlled study. N Engl J Med 1987;314:185-91.
12. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
13. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting inhuman immunodeficiency virus infection. N Engl J Med 1995;333:83-8.
14. Hellerstein MK, Meydani SN, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat: influence of prostaglandins. J Clin Invest 1989;84:228-35.
15. Roubenoff R, Freeman LM, Smith DE, Abad LW, Dinarello CA, Kehayias JJ. Adjuvant arthritis as a model of inflammatory cachexia. Arthritis Rheum 1997;40:534-9.
16. Hoshino E, Pichard C, Greenwood CE, et al. Body-composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol 1991;260:E27-E36.
17. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988;167:1211-27.
18. Strassmann G, Mazui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon 26 tumor. J Immunol 1993;150:2341-5.
19. Billingsley KG, Fraker DL, Strassmann G, Loeser C, Fliot HM, Alexander HR. Macrophage-derived tumor necrosis factor and tumor-derived of leukemia inhibitory factor and interleukin-6: possible cellular mechanisms of cancer cachexia. Ann Surg Oncol 3:29-35.
20. Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellman DB. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992;19:1505-10.
21. Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994;93: 2379-86.
22. Warren RS, Starnes HF Jr, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987;122:1396-1400.
23. Tracey KJ, Lowry SF, Cerami A. Cachectin: a hormone that triggers acute shock and chronic cachexia. J Infect Dis 1988;157:413-20.
24. Moldawer LL, Rogy MA, Lowry SF. The role of cytokines in cancer cachexia. J Parenter Enteral Nutr 1992;16:43S-9S.
25. Wigmore SJ, Fearon KCH, Maingay JP, Ross JA. Down-regulation of acute phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997;92:215-21.
26. Falconer JS, Fearon KCH, Plester CE, Ross JA, Cartner DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219: 325-31.
27. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991;5: 1405-17.
28. Grundfeld C, Kotler DP. Pathophysiology of the AIDS wasting syndrome. AIDS Clin Rev 1992;191-224.
29. Laviano A, Meguid MM, Yang ZJ, Gleason JR, Cangiano C, Fanelli FR. Cracking the riddle of cancer anorexia. Nutrition 1996; 12:706-10.
30. Bodnar RJ, Pasternak GW, Mann PE, Paul D, Warren R, Donnei DE. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res 1989;49: 6280-4.
31. Navikas V, Link J, Persson C, et al. Increased mRNA expression of IL-6, IL-10, TNFa, and perform in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:484-9.
32. Stein TP, Koerner B, Schluter MD, et al. Weight loss, the gut and the inflammatory response in AIDS patients. Cytokine 1997; 9:143-7.
33. Aukrust P, Liabakk N-B, Muller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-α (TNFα) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-4.
34. Michihiko S, Yamamoto N, Shinozaki F, Shimada K, Soma G, Kobaysahi N. Augmentation of the in-vitro HIV replication in peripheral blood mononuclear cells of AIDS and ARC patients by tumor necrosis factor. Lancet 1989;1:1206-7.
35. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-KB sites in the long terminal repeat. Proc Natl Acad Sci: USA 1989; 86:5974-8.
36. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
37. Moreira AL, Sampaion EP, Zmuidzinas A, et al. Thalidomide exerts it inhibitory actions on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
38. Makonkawkeyoon S, Limsom-Pobre RN, Moreira AL, Schaauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90: 5974-8.
39. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: randomized, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501-7.
40. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-57.